SnagRx GLP-1 Reviews: The $69 Catch, the Complaints, and Our 2026 Verdict

The short answer

SnagRx is a real, operating telehealth company — but the $69 price in the ad is not a monthly bill. It is the effective rate when you pay $828 up front for twelve months. SnagRx's own Terms list the true month-to-month price as $99 for compounded semaglutide and $149 for compounded tirzepatide.

A related advertised-price-versus-refill problem appears in two visible complaints on the shared parent-company BBB file.

Here is what most people searching SnagRx GLP-1 reviews are really asking: this price is way below everyone else, so what's the catch? You deserve a straight answer, so we read the fine print, pulled the company's public business records, and checked the complaint file. The catch is not that the company is fake. It isn't. The catch is that the number in the ad and the number that hits your card are two different numbers — and the company's own pages don't agree on when they charge you, how long you have to cancel, what you get back if you're turned down, or where the service is available.

We'll show you all of it. Including the part where the "old price" they cross out on their homepage is the same number two complainants say they were charged at refill.

Is SnagRx right for you?

Quick verdict

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

What we actually verified

We want you to know exactly how solid this is.

What we read, on August 11, 2026: SnagRx's homepage and pricing claims. SnagRx's Terms & Conditions, last updated July 27, 2026. SnagRx's separate Cancellation and Refund Policy, last updated February 10, 2026. SnagRx's Medical Consent, also dated February 10, 2026. The Better Business Bureau business profile and complaint file for Modern Metabolic Medicine, Inc. The Embody and RodeoMeds websites and Embody's Terms. FDA's current compounding guidance, FDA's current warning page for unapproved GLP-1 drugs, the current FDA-approved Wegovy and Zepbound prescribing information, FDA's Triad Rx closeout letter, and Ro's current pricing and insurance pages.

What we did not do: We did not sign up. We did not order medication. We did not call or message support. We did not test the cancellation or refund process. We could not confirm which pharmacy would fill any individual prescription, and we could not independently verify the 4.8-star rating or 125,000-customer claim SnagRx displays on its own site.

This is a public-document audit, not a firsthand treatment review. We'd rather tell you that than pretend.

Provider-stated versus independently checked

The right treatment path isn't the same for everyone

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized path with source-checked pricing before you choose.

→ Not sure whether compounded or FDA-approved fits your situation? Take the Find My GLP-1 Path quiz — about 2 minutes.

First, the honest problem

We're going to say the worst thing about SnagRx before we say anything good, because you should be able to tell whether we're on your side or theirs.

SnagRx does not sell FDA-approved medication, and it will not bill your insurance.

If you want Wegovy or Zepbound — the FDA-approved branded drugs with FDA-reviewed prescribing information — SnagRx is not that path. If you were hoping insurance would cover this, SnagRx's Terms say its affiliated clinicians are out-of-network and do not guarantee that insurance, an HSA, or an FSA will reimburse you. If that is what you need, stop reading and check coverage instead. Our Ro insurance guide explains the separate membership and medication bills and links to Ro's free coverage checker.

But here's why people still choose a program like this one.

Because SnagRx skips insurance completely, there is no insurance prior authorization. No insurance denial letter. No waiting for an insurer to decide whether it will pay. You pay cash and know the listed program price at the start — although SnagRx's Terms also reserve the right to notify you if the final charge varies by prescribed medication or selected pharmacy.

For someone whose insurance already said no — or who has no useful coverage for weight medication — that may be the only door that's open.

So the real question isn't whether compounded and cash-pay is acceptable. For a lot of you, it's the only workable option. The real question is whether this cash-pay company charges what it says it charges.

That's where it gets interesting.

How much does SnagRx actually cost?

SnagRx lists compounded semaglutide at $99 per month and compounded tirzepatide at $149 per month when billed monthly. The advertised $69 and $119 rates are effective monthly costs that require paying for twelve months up front — $828 for semaglutide or $1,428 for tirzepatide. All multi-month plans automatically renew for the same length unless you cancel in time.

The homepage says "GLP1 for $69/month." Big number, front and center.

Their Terms & Conditions say something different. Here it is, straight from the pricing section:

Compounded semaglutide

Compounded tirzepatide

Source: SnagRx Terms & Conditions, “Program Options & Pricing,” last updated July 27, 2026. Verified August 11, 2026.

Read those tables again and you'll see it. The $69 in the ad is real — it's just the math, not the bill. To get $69 a month, you hand over $828 today.

The Terms add one more sentence you should not miss: the final charge may vary based on the prescribed medication and selected pharmacy, and SnagRx says support will notify you if a pricing variance occurs. That sits awkwardly beside the homepage promise of "Locked-In Flat Pricing for Life." Confirm the final total on the checkout screen, not just the rate on the homepage.

So is the annual plan a good deal or not?

Honestly? The savings are smaller than the risk.

Paying monthly for a year costs $1,188. Paying up front costs $828. You save $360 — about $30 a month.

For tirzepatide it's the same $360 gap: $1,788 versus $1,428.

Thirty dollars a month is real money. We're not going to pretend it isn't. But think about what you're buying with that $360: you're buying the right to find out whether this company works for you before you're all-in. You haven't met the clinician yet. You don't know which pharmacy fills your prescription. You don't know how the medication feels in your body. You don't know how fast support answers when something goes sideways.

Our read: for a first-time customer, $30 a month is a cheap price for the ability to walk away. Take the monthly plan. If it goes well, ask what longer plan is available then and read the checkout terms again before switching.

One more thing about that price

The homepage shows tirzepatide with "$399" crossed out above the sale price. The Terms list the retail comparison price as $349. Their own two documents don't agree on what the "before" price even was.

Hold onto that $399 number. It comes back later, and not in a good way.

🧮 The SnagRx plan and cancel-by worksheet

Use this table to see the bill, not just the advertised rate:

Your cancel-by rule: find the renewal date shown on your receipt or account, then count back at least five days. That is the stricter of SnagRx's two published deadlines.

Example only: if SnagRx shows August 11, 2027 as your annual renewal date, your five-day cancel-by date is August 6, 2027. Use the date in your own account because billing dates can differ.

Before you pay, save these five things:

• The plan length
• The total charge today
• The effective monthly rate
• The renewal date
• The cancellation and refund text shown at checkout

A one-line price summary can tell you "$69 requires an annual plan." It can't save your checkout screen or put your exact cancel-by date on your calendar. Do both before you submit payment.

→ Ready to see your real number? Check SnagRx eligibility and confirm today's full checkout total before you pick a plan length.

Is SnagRx legit, and is it the same company as Embody?

SnagRx is a real business with a named legal operator, published Terms, a listed phone number, a named clinical network, and four listed partner pharmacies. SnagRx and Embody are sister brands operated by the same parent company, Modern Metabolic Medicine, Inc. There is no evidence that Embody owns SnagRx or that SnagRx is an Embody spin-off.

Let's clear up the legitimacy question first, because it's the one keeping you up.

SnagRx is not an anonymous storefront with no company name behind it. Its Terms say Modern Metabolic Medicine, Inc. owns and operates snagrx.com. SnagRx says prescribing decisions are made by clinicians in the OpenLoop Health network, and it lists four partner pharmacies. We did not test the phone line, a clinical visit, or a pharmacy fill, so those care and support claims remain provider-stated rather than firsthand findings.

That's the good news. Now here's the part almost nobody has published.

One parent company, three brands

We were checking who owned SnagRx and found something else: the same parent company runs at least two other consumer brands.

Here's the paper trail. Every link below is public and you can check it yourself in about five minutes.

All verified August 11, 2026.

That last group is the strongest evidence. RodeoMeds isn't just related to Embody — its checkout runs on an Embody-domain subdomain, and its support email uses an Embody mail domain. These aren't three unrelated companies that happen to share an investor. They're consumer brands under one legal operator with shared infrastructure.

To be precise about it

We want to be careful here, because precision matters and a lot of pages get this wrong.

Embody does not own SnagRx. Nothing we found supports that. SnagRx is not a "spin-off" of Embody either. The accurate description is: SnagRx and Embody are sister brands operated by the same parent company. One company, several front doors.

Why this matters to your wallet

If you've been comparing GLP-1 providers, there's a decent chance SnagRx and Embody both showed up on your list. You might have thought you had two separate companies to weigh against each other.

You have one parent company with two price sheets.

And they're not the same price sheet:

SnagRx pricing from its Terms dated July 27, 2026. Embody pricing from its active-program Terms updated July 1, 2026. Verified August 11, 2026. Multi-month plans require prepayment; confirm the checkout total before buying.

Same parent company. Same four listed pharmacies. Same named clinical network. Twenty dollars a month apart at the monthly tier — and the published annual rates meet at the same number.

That's not a scandal. Companies run multiple brands all the time. But you should know that "switching from SnagRx to Embody" is not switching parent companies. It is changing brands inside the same company. The brands also share one parent-company BBB file, so do not treat Embody as an independent escape hatch from that record.

→ Want to see how the sister brand's pricing and terms compare? Read our separate Embody GLP-1 review.

Where do SnagRx's own documents contradict each other?

SnagRx currently publishes four sources that give different answers to basic buyer questions: the homepage, the Terms & Conditions dated July 27, 2026, the Cancellation and Refund Policy dated February 10, 2026, and the Medical Consent dated February 10, 2026. They conflict on charge timing, cancellation, denial refunds, state coverage, price promises, and whether refunds exist at all.

This is the part that took the longest to find and the part we think matters most.

SnagRx's refund policy and Medical Consent have not been updated since February. The Terms were updated in July. The pages still do not line up. So the company is publishing more than one rulebook at the same time, and a buyer has to work out the conflict before paying.

The Terms are the newest document and say they form the entire agreement for use of the site. That still does not make the conflicting checkout promises safe to ignore. Save the exact terms you accept.

Here's every material conflict we found, what each one means, and what to do about it.

The SnagRx receipts

All conflicts verified August 11, 2026 by reading the live pages the same day.

The refund window is smaller than you think

This one deserves its own paragraph because it's the most expensive thing on this page.

The refund policy says you can get money back for the current billing cycle only if your medication has not been ordered. For new patients, it says that point will generally be intake submission if no live video visit is required, or the end of the video visit if one is required.

Now stack that against the Terms, which say you're charged at checkout.

Put together, the ordinary change-of-mind sequence may look like this: you pay → you complete the intake → the medication is ordered → the ordinary refund window closes.

That means the practical refund window may be the time between checkout and intake submission. The exact timing can vary, so do not assume you have a cooling-off period after you finish the form.

We are not saying SnagRx does this on purpose to trap people. We're saying that's what the live documents describe when you read them side by side, and almost nobody reads them side by side. Now you have.

What do SnagRx complaints and reviews actually show?

The Better Business Bureau gives Modern Metabolic Medicine — the parent company behind SnagRx, Embody, and RodeoMeds — an F rating. As of August 11, 2026, the shared file shows 21 complaints in three years, all 21 unanswered. The complaints break down as 11 service issues, 9 billing issues, and 1 product issue. This is not a SnagRx-only complaint count.

Here's where the fine print stops being theoretical.

The BBB file, exactly as it reads

• Rating: F. The business is not BBB accredited.
• Reason for the F: failure to respond to 21 complaints, plus the complaint count itself.
• 21 total complaints in the last three years. All 21 were closed in the last twelve months. All 21 are marked unanswered.
• Complaint types: Service or Repair Issues (11), Billing Issues (9), Product Issues (1)
• BBB file opened: May 5, 2026
• Business start date: December 19, 2025
• Alternate names on the same file: SnagRx, Embody, and RodeoMeds

Source: BBB business profile and BBB complaint file for Modern Metabolic Medicine, Inc. Verified August 11, 2026.

Two things you need to hold at once.

First, be fair to the company. The parent company started in December 2025. It is not even one year old. BBB accreditation is voluntary. BBB also says complaint text may show only part of the complaints filed, and a complaint is an allegation, not a proven finding. An F rating is not proof of fraud. It does not tell you whether a medication is potent, sterile, or right for you.

Second, be fair to yourself. Twenty-one complaints and twenty-one non-responses is not a mixed response record. It tells you something specific and useful: when customers used BBB to ask this parent company to fix a problem, the company did not answer any of the 21 complaints shown in the count. Do not prepay money you would need help recovering.

Important: these complaints are not all about SnagRx

The BBB file is a parent-company profile. It covers SnagRx, Embody, and RodeoMeds together.

BBB currently displays five complaint narratives on the public page. Two name Embody. None names SnagRx. The other three do not identify the consumer brand in the text BBB shows.

So we're not going to tell you "SnagRx has 21 complaints." That is not what the record proves.

What we can tell you is that SnagRx shares the legal operator, phone number, and BBB file tied to the record. The support and billing pattern is relevant to your purchase, but the brand attribution has limits.

Two refill-price complaints and one dose-support complaint

The five published narratives are not a full sample of all 21 complaints. These are the three that line up most closely with the pricing and dose questions on this page.

June 19, 2026 — billing. A complainant says the advertised monthly price was $199 and the second-month charge was $399. The complaint says the customer asked to cancel but kept receiving offers instead of a completed cancellation.

June 30, 2026 — billing. A complainant says the expected price was $149, then a $399 refill charge appeared. The complaint says support was asked to stop the order, a discount was offered, the cancellation request was repeated, and a shipping notice arrived anyway.

July 6, 2026 — dose and support. A complainant says an ad promised $79 per month for life, then the company planned to ship a weekly amount shown as 0.25 after the person had been using 1.0. The public text does not identify the drug, its units, or the consumer brand. The complainant says refund requests went unanswered for more than a month.

These are consumer allegations, not findings by BBB or a court. But they point at the exact places where SnagRx's own documents are already unclear: refill price, cancellation, refunds, and dose confirmation.

About that $399

Remember the crossed-out "Was $399" on SnagRx's homepage?

That is the same number the June 19 and June 30 complainants say appeared at refill.

We are not going to tell you those are connected, because the public record does not prove it. We're telling you the number matches. Confirm the exact renewal amount in writing before you let any refill run.

If you're switching from another provider

Do not assume a new company will continue the number printed on your old vial, syringe, or pen.

The July 6 complaint leaves out the drug and units, so it cannot prove the proposed dose was wrong. It does prove why the question matters. Before anything ships, ask for:

• The medication name
• Your prescribed dose in milligrams per injection
• The vial concentration in milligrams per milliliter
• The volume to inject in milliliters or syringe units
• Whether the clinician is restarting titration and why

If the written order and the label do not match, do not guess. Ask the prescribing clinician and dispensing pharmacy before injecting.

Why we're not showing you a glowing testimonial block

You've probably noticed there are no hand-picked five-star quotes on this page.

That's deliberate. SnagRx displays an "Excellent 4.8/5" badge on its own website, but the badge does not name a review platform or show how many reviews sit behind the number. We could not independently verify the calculation.

SnagRx's footer also says images representing testimonials may use models and that site materials may be generated or enhanced with artificial intelligence.

We could have grabbed positive reviews from the sister brand and relabeled them. Plenty of pages do. We're not doing that — different brand, different purchase path, and you'd have no way to know.

When SnagRx publishes a review source with a visible count and method, we can check it. Until then, the honest label is provider-displayed, not independently verified.

→ If the shared complaint record is a dealbreaker — and that is a reasonable call — use the Find My GLP-1 Path quiz to compare other paths.

Are SnagRx's semaglutide and tirzepatide FDA-approved?

No. SnagRx markets compounded semaglutide and compounded tirzepatide and says they are dispensed by 503A pharmacies. Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness, or quality before sale, and they are not FDA-approved generics.

This is the most important medical thing on the page, so let's make it plain.

What "compounded" actually means

A 503A compounding pharmacy works under patient-specific prescription rules. That is a real part of American healthcare. It can be useful when an approved product cannot meet one patient's documented medical need.

Here is what it is not: it is not the same as an FDA-approved drug. When an approved manufacturer sells Wegovy or Zepbound, FDA has reviewed that product's evidence, manufacturing controls, label, and approved uses. A compounded version does not go through that premarket approval process.

We're not going to tell you compounded medication is "the same as" the brand-name drug. It isn't, and FDA spent 2026 warning telehealth companies not to make that claim.

We're also not going to tell you every compounded prescription is illegal or useless. The legal question turns on the pharmacy, the prescription, the formulation, the patient's documented need, and whether the order meets the conditions of federal and state law.

Can a 503A pharmacy still compound semaglutide or tirzepatide in 2026?

Sometimes, for an identified patient — but the old shortage-based mass-copying window is over.

FDA's April 1, 2026 update says semaglutide and tirzepatide are not on the federal drug shortage list. A 503A pharmacy cannot regularly or in large amounts make a product that is essentially a copy of a commercially available approved drug. One path that can still apply is a prescriber's documented finding that a change creates a significant difference for one identified patient. FDA also says it does not currently plan to take action under this specific copy rule when a compounder fills four or fewer prescriptions of that particular copy in a calendar month. That is a narrow enforcement policy, not FDA approval and not a mass-market exception.

SnagRx says its products are prepared for individual patients when commercially available options are not suitable. That is the right kind of concept. But a homepage sentence cannot prove that each order meets the patient-specific prescription rules and other conditions that apply.

Ask this before you pay:

"What documented, patient-specific difference makes the compounded product appropriate for me instead of an available FDA-approved product? Will that determination appear in my medical record or prescription?"

A licensed clinician should answer that based on your case. A sales page cannot answer it for everyone at once.

SnagRx uses wording FDA has been policing

SnagRx's homepage says its compounded products are "the same medications that people are talking about all over the country." It also says compounded GLP-1s are produced in "FDA-regulated facilities."

Read that carefully. FDA said in 2026 that companies cannot market compounded GLP-1 products as the same as FDA-approved drugs, as approved generics, or with wording that falsely suggests FDA approval. A facility may be subject to some FDA authority without the finished compounded drug being FDA-approved.

SnagRx also states elsewhere that its medications are not FDA-approved. That disclosure is correct. We are not saying FDA has made a finding against SnagRx. We are saying the homepage wording is close to the kind of sameness claim FDA identified. Do not let "FDA-regulated facility" erase "not FDA-approved" in your head.

The tirzepatide dosing text is broken, not proven dangerous

Here's something the public page makes hard to read, and precision matters.

SnagRx publishes a "standard protocol" on its homepage. The semaglutide row is written as 0.25 mg per week for four weeks, then 0.5 mg per week for eight weeks. The next row, shown with a tirzepatide image, is printed as "10/mg" for four weeks and "20/mg" for eight weeks.

That is not a usable dose instruction. The unit order is broken. It does not say whether 10 and 20 are:

• Total milligrams in a multi-dose container
• Milligrams per milliliter
• Syringe units
• A weekly dose
• Or a simple website typo

The FDA-approved Zepbound schedule starts at 2.5 mg once weekly for four weeks, then rises to 5 mg, with increases of 2.5 mg only after at least four weeks at the current dose. Its maximum approved dose is 15 mg once weekly.

But that does not prove SnagRx is prescribing 10 mg and 20 mg weekly. Current Zepbound KwikPen labels also use 10 mg/2.4 mL for a pen that delivers four 2.5 mg doses and 20 mg/2.4 mL for a pen that delivers four 5 mg doses. A container total is not the same thing as one injection.

So the correct finding is not "SnagRx starts patients at four times the approved dose." The correct finding is: the public dosing text is too malformed to tell a patient what it means.

Never take a dose off a marketing page. Before your first injection, get all four parts in writing:

1. Dose per injection in milligrams
2. Concentration in milligrams per milliliter
3. Volume per injection in milliliters or syringe units
4. Frequency and date of the next increase

Then compare the written order with the pharmacy label. If they do not match, do not inject until the prescriber and pharmacy resolve it.

One more mismatch in the weight-loss claim

SnagRx's advertised results carry a footnote. It says the result is based on self-reported data from patients without diabetes who reached and maintained 2.4 mg per week of GLP-1 treatment, with diet and activity changes.

But the twelve-week semaglutide protocol displayed on the same homepage shows 0.25 mg per week for four weeks and 0.5 mg per week for the next eight.

The page does not explain when those patients reached 2.4 mg, which medication the claim covers, how many patients were measured, how they were selected, or how the 15% figure was calculated. That does not prove nobody loses weight. It means the marketing result cannot be tied to the displayed first-twelve-week plan from the information provided.

FDA has received safety and quality reports about compounded GLP-1s

As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA also received multiple reports of dosing errors with compounded injectable semaglutide, some requiring hospitalization. It warns about fraudulent labels and injectable products arriving warm or without enough refrigeration.

Those reports do not prove a problem with your future SnagRx vial. FDA says it is not always possible to tell whether the compounded drug caused a reported event or whether other factors contributed. The practical lesson is simpler: verify the pharmacy, read the label, measure the prescribed volume exactly, and do not use an injectable product that arrives warm or without adequate refrigeration.

Who should not start without a clinician's clearance

Do not use this review as a screening form. The actual prescription label and your clinician control.

The current FDA-approved labels for Wegovy and Zepbound list a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 as contraindications. They also list prior serious hypersensitivity to the drug or its ingredients. The Zepbound label says to stop when pregnancy is recognized; the Wegovy label has pregnancy-specific instructions too.

That is not the whole safety screen. Your clinician needs your medication list, medical history, pregnancy status or plans, and any past reaction before deciding whether treatment is appropriate.

→ If you'd rather use an FDA-approved medication and check insurance or current cash pricing, see our Ro weight-loss coverage and cost guide.

Which pharmacy does SnagRx actually use?

SnagRx names four partner pharmacies: RedRock Pharmacy in Utah, Health Warehouse in Kentucky, Precision Compounding Pharmacy in New York, and Triad Rx in Alabama. Naming four partners does not tell an individual patient which pharmacy will fill a prescription, and SnagRx's Terms allow prescriptions to be transferred among pharmacies.

Most review pages list these four names and move on. That's not useful to you, so let's go further.

This table reports SnagRx's partner list. It does not prove which pharmacy will fill your order or which product each pharmacy supplies. Verified August 11, 2026.

Here's the part that matters: four names on a website is not the same as knowing who prepared your medicine. SnagRx's Terms say a prescription may be transferred among pharmacies because of availability, pricing, operational needs, or other factors.

So the pharmacy that fills your first order may not be the one that fills your fourth.

Why you should care which one it is

The dispensing pharmacy controls the label on the vial, the concentration, storage directions, beyond-use date, and the pharmacy contact for product questions. The telehealth company controls other parts of the experience. When the issue is the vial, start with the pharmacy and include the prescribing team.

Ask which pharmacy is assigned before it ships. Then look up that pharmacy through the state board of pharmacy for the state where it is located. Also ask whether it is authorized to ship that specific prescription into your state.

One old FDA record you should understand — and not overread

FDA sent Triad Rx a warning letter in 2019. FDA's May 3, 2023 closeout letter says Triad had adequately addressed the cited violations and, at that time, no longer produced sterile drug products.

That is a closed historical matter, not proof of a current violation. It does leave a practical question because SnagRx sells injectable products and lists Triad as a partner in 2026:

"Does Triad Rx fill injectable GLP-1 orders for SnagRx today, and what current license or registration covers that work?"

The answer may be that Triad fills a different product or that its operations changed after 2023. Ask instead of guessing.

What to check the moment the box arrives

• Your name is on the label
• The pharmacy matches what you were told
• The medication name matches the prescription
• The concentration and injection volume match the written order
• The seal is intact and nothing is cracked or leaking
• Storage instructions and a beyond-use date are included
• The package is not warm if refrigeration was required

FDA tells patients not to use an injectable GLP-1 that arrives warm or without enough refrigeration. Photograph the box, coolant, packaging, and vial. Then contact the dispensing pharmacy and prescribing clinician for instructions.

Can you cancel SnagRx, and can you get a refund?

SnagRx allows cancellation by email, through the account portal, or by replying to a SnagRx email. Its current Terms require at least five days' notice before the end of the prescription period; its older refund policy says 72 hours before the billing date. Prepaid amounts for the current term are generally not refunded when you cancel early.

Cancellation is where the money actually gets lost, so read this section even if you skim the rest.

The safest way to cancel

1. Find the exact renewal date. Use the receipt or account display, not a guess based on the day the box arrived.
2. Count back at least five days. That is the stricter of the two published deadlines.
3. Put the date in your calendar now, with an earlier reminder.
4. Send the cancellation in writing to [email protected], and submit it through the account portal too.
5. Say you are cancelling automatic renewal, not only pausing treatment or asking a question.
6. Ask for written confirmation with the effective date and the amount of any final charge.
7. Check the card statement after the date the renewal would have run. SnagRx's Terms say the descriptor is OPNLP-SNAGRX.

That last detail catches people. Save it with your receipt.

Will you get money back for months you didn't use?

Under the current Terms, generally no.

The language says you agree to the full commitment period selected and refunds are not issued for unused portions. Cancelling stops a future renewal. It does not normally refund the term you already bought.

If you buy twelve months for $828 and stop in month three, plan on the $828 remaining spent unless SnagRx gives you a written exception or the law requires one.

What if the clinician says no?

This is the conflict we flagged earlier, and it can be worth the full charge.

The homepage and refund policy promise a full refund if a provider disqualifies you. The Terms say consultation fees are not refundable and an ineligible patient may receive a refund for medication not yet dispensed. The Medical Consent says there are no refunds or exchanges.

Those rules do not line up. Before you pay, send this exact question:

"If your clinician decides I am not eligible, will you refund every dollar I paid, including any consultation fee? What amount is nonrefundable, and how many business days will the refund take?"

Get the answer in writing. Save the answer and the version of the checkout terms you accepted.

The 30-day arbitration opt-out almost nobody sees

SnagRx's Terms include mandatory individual arbitration and a class-action waiver, while preserving qualifying small-claims cases. The Terms also give you 30 days from the date you agreed to them to opt out.

They say the notice must include your name, home address, the email address or phone number tied to the account, and a clear statement that you are opting out of the arbitration agreement.

The Terms list both a mailing address and [email protected] for the opt-out. Because the ZIP code in the Terms conflicts with BBB's ZIP for the same street address, the email route gives you a clean timestamp. Keep the sent message and any reply.

This is legal-contract information, not legal advice. Read the version of the Terms you accepted because it can change.

If you're already charged and stuck

1. Send a clear written cancellation and refund request. Keep screenshots and timestamps.
2. Quote the checkout promise or policy that supports your request.
3. Ask the card issuer what dispute rights and deadlines apply. Describe the facts accurately; do not call an authorized purchase fraud just because the descriptor looks unfamiliar.
4. Know that SnagRx's Terms say a chargeback may suspend the account, so save records and address any care or refill issue first.
5. File a BBB complaint or contact your state attorney general's consumer protection office if the company does not resolve it.

→ If you've read the commitment and refund terms and they still work for you, confirm SnagRx's live checkout total and save the screen before paying.

Is SnagRx available in every state?

SnagRx's own website gives two different answers. Its Terms say services are offered in all 50 states plus Washington, D.C., while an alert on the homepage says SnagRx cannot provide services in Mississippi or Louisiana. Confirm your state in the live intake before you pay.

Short section, simple point.

The Terms say all 50 states plus D.C., while warning that some services may not be available everywhere. The homepage alert names Mississippi and Louisiana as excluded.

Telehealth availability can change with clinician licenses, prescribing rules, and pharmacy shipping authority. Enter your state in the intake, make sure the clinician and pharmacy can serve it, and save the eligibility screen.

If you're in Mississippi or Louisiana, assume you're excluded unless the live intake and support both confirm otherwise in writing.

How does SnagRx compare, and when is something else better?

SnagRx's $99 month-to-month semaglutide price is low on its face, and the program price includes the medication SnagRx offers. What you trade for it is FDA approval, insurance billing, a long company track record, clear policy language, and an answered BBB complaint record. Whether that trade works depends on which of those you need.

This table is built to avoid a common trick: comparing an all-in compounded program with only the membership fee from an FDA-approved program.

SnagRx, Embody, and Ro figures verified August 11, 2026. Ro currently lists $39 for the first membership month, then $149 month-to-month, $99/month on a three-month prepaid plan, $89/month on a six-month prepaid plan, or $74/month on an annual prepaid plan. Medication costs extra. Offers, doses, and eligibility change, so use the live checkout.

If you want an FDA-approved drug, Ro is the clearer lane of the three. Ro currently offers FDA-approved options, separates the membership from the medication bill, and provides an insurance concierge for Wegovy pen, Zepbound autoinjector, and Ozempic. Coverage is not guaranteed, and some Ro options are cash-pay only.

If you want the lowest published month-to-month compounded price from this parent company, Embody's active Terms list $79 for semaglutide and $129 for tirzepatide — $20 below SnagRx at each monthly tier. That is a price comparison, not a safer-company recommendation. The brands share a parent and BBB file.

If you're not sure which lane you belong in, that is the most common situation. Use the Find My GLP-1 Path quiz before opening three checkout tabs and guessing.

Who should choose SnagRx, and who should walk away?

SnagRx fits a narrow reader: someone paying cash, who knowingly accepts compounded medication after a clinician documents why it fits, who takes the $99 or $149 month-to-month plan instead of chasing the annual headline rate, and who saves every term and receipt. Readers who need FDA-approved medication, insurance support, refund flexibility, or a proven response record have better paths.

We'd rather lose you here than have you regret this in six weeks. So let's be direct.

Consider SnagRx only if all of these are true

• Insurance is not useful for your chosen path, or you have decided to pay cash
• You understand the prescription would be compounded, not an FDA-approved brand or generic
• A licensed clinician documents why the compounded option is appropriate for you
• You choose month-to-month for the first term instead of prepaying twelve months
• You can afford the full charge shown at checkout
• You put the renewal and cancel-by dates in your calendar immediately
• You keep records and will question any mismatch before injecting or paying a refill

Skip SnagRx if any of these are true

That complaint line deserves a word. Reading "21 unanswered complaints" and walking away is not overreacting. It is a rational way to weight support risk. A low price does not obligate you to accept a record you do not like.

What should you check before paying SnagRx or any GLP-1 provider?

The shared parent-company complaints center on billing, communication, and one unclear dose dispute. A paper trail will not prevent every problem, but it can expose a mismatch before payment or injection and make a later dispute much easier to prove.

Take this with you. It works for any online GLP-1 provider, not just this one.

1. Choose month-to-month until the company has earned a longer commitment. For SnagRx, that means $99 for semaglutide or $149 for tirzepatide instead of $828 or $1,428 up front.
2. Screenshot the checkout page showing the medication, plan length, total charge, and renewal terms.
3. Write down the renewal date and set a reminder at least seven days before it.
4. Know the statement descriptor. SnagRx's Terms say OPNLP-SNAGRX.
5. Confirm your state in the live intake before trusting the advertised availability.
6. Get the dose, concentration, and injection volume in writing and compare all three with the pharmacy label.
7. Ask which pharmacy will fill the prescription, whether it may change, and whether it can ship that product into your state.
8. Save the medical-eligibility and refund promise shown before payment.
9. Opt out of arbitration within 30 days if you choose to preserve the options described in the Terms.
10. Cancel in writing and save every email. The receipt, checkout screen, label, and timestamps are the case if a dispute happens.

Five questions to send support before you pay

Copy and paste these. Their answers — or their silence — will tell you a lot.

1. Is my cancellation deadline 72 hours or five days, and what exact date applies to this order?
2. Am I charged at checkout or after intake, and what exact total will hit my card today?
3. If the clinician says I am not eligible, will every dollar be refunded, including any consultation fee?
4. What patient-specific, documented difference makes this compounded prescription appropriate for me, and can the final price change by pharmacy or formulation?
5. Which pharmacy will fill it, and what are my exact dose in mg, concentration in mg/mL, and injection volume?

→ If you've worked through the checklist and SnagRx still fits, open the live intake and confirm the full total before submitting payment.

How did we review SnagRx?

This is a dated public-document audit. We compared SnagRx's marketing claims with its legal and consent pages, traced its parent company and related brands, read the shared BBB complaint file, checked current FDA compounding policy and drug labels, and recalculated every published plan.

Who wrote this: The RX Index editorial team. No physician reviewed this page. This is a provider, policy, and pricing review. It is not medical advice.

What we did: Read SnagRx's homepage, Terms & Conditions, Cancellation and Refund Policy, and Medical Consent. Identified the named legal operator and related brands. Checked the BBB profile and complaint page for Modern Metabolic Medicine, Inc. Traced RodeoMeds' checkout and support domains. Compared SnagRx and Embody price ladders. Read FDA's April 2026 compounding update, 2026 GLP-1 advertising enforcement statements, unapproved-GLP-1 safety page, current Wegovy and Zepbound labeling, and Triad Rx closeout letter. Checked Ro's current membership, medication, and insurance pages. Calculated every total and effective monthly cost from the companies' published figures.

What we didn't do: We did not sign up, order medication, test support, receive a clinical review, inspect a vial, or attempt a cancellation or refund. We could not confirm any patient's assigned pharmacy, formulation, dose, or patient-specific compounding rationale. We could not independently verify SnagRx's displayed 4.8-star rating or 125,000-customer claim.

Read our full provider-review methodology for how we separate provider claims, public records, and firsthand evidence.

The five RX Index pillars

We score providers on clinical legitimacy, care quality, transparency, access, and cost. We are not assigning SnagRx a numeric score, because a number would imply precision we do not have for a company this new and a purchase path we did not test.

Why this page exists: The low price is easy to see. The full bill, policy conflicts, shared corporate record, current compounding rules, and broken dosing text take hours to piece together. We did that so you don't have to.

SnagRx GLP-1 reviews: frequently asked questions

Is SnagRx legit?

Yes, in the narrow business-identity sense. SnagRx has a named legal operator, published Terms, a listed phone number, a named clinical network, and four listed pharmacy partners. That does not erase the shared parent company's F-rated BBB file or the conflicts among SnagRx's own pages.

Is SnagRx a scam?

We found a real legal operator and operating website, not an anonymous storefront. We also found enough pricing, policy, complaint, and disclosure problems that you should verify the full charge, prescription details, refund rule, and pharmacy in writing before paying.

Is SnagRx owned by Embody?

No. SnagRx and Embody are sister brands operated by Modern Metabolic Medicine, Inc. BBB lists both, plus RodeoMeds, as alternate names on one business file.

How much is SnagRx semaglutide?

The Terms list $99 billed monthly, $267 for three months, $474 for six months, or $828 for twelve months. The advertised $69 is the effective monthly rate on the twelve-month plan, not a $69 monthly charge.

How much is SnagRx tirzepatide?

The Terms list $149 billed monthly, $417 for three months, $774 for six months, or $1,428 for twelve months. The advertised $119 is the effective monthly rate on the twelve-month plan.

Does SnagRx really charge $69 a month?

Not as a month-to-month bill. Under the published Terms, the $69 rate requires paying $828 for twelve months at once.

Are SnagRx medications FDA-approved?

No. SnagRx markets compounded semaglutide and tirzepatide. Compounded drugs are not FDA-approved, are not FDA-approved generics, and are not reviewed by FDA for safety, effectiveness, or quality before sale.

Can 503A pharmacies still compound these drugs in 2026?

They can prepare patient-specific prescriptions that meet 503A conditions. But semaglutide and tirzepatide are off the FDA shortage list, so the old broad shortage path is over. A 503A pharmacy cannot regularly make drugs that are essentially copies, subject to the law and FDA's stated enforcement policy. Ask what documented difference applies to you.

What is wrong with SnagRx's tirzepatide dose chart?

The public chart prints "10/mg" and "20/mg," which are not usable dose directions. Those numbers could refer to a container total, concentration, syringe units, or a typo. Get the dose in mg, concentration in mg/mL, and injection volume in writing from the clinician and pharmacy.

Which pharmacy does SnagRx use?

SnagRx lists RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx. Its Terms allow pharmacy transfers, so ask which one is assigned to your exact order.

Does SnagRx take insurance?

No. SnagRx is cash-pay. Its Terms say affiliated clinicians are out-of-network and do not guarantee insurance, HSA, or FSA reimbursement. Check with your plan administrator before assuming an expense qualifies.

Is SnagRx available in all 50 states?

Its own pages disagree. The Terms say all 50 states plus D.C. A homepage alert excludes Mississippi and Louisiana. Confirm in the live intake before paying.

Can you cancel SnagRx anytime?

You can request cancellation of future renewal. That does not mean a prepaid current term is refundable. Cancel at least five days before the term ends because that is the stricter published deadline.

When does SnagRx charge the card?

The current Terms say the initial charge occurs at checkout. The older refund policy says the charge occurs when intake is completed. The homepage also places payment before intake. Assume checkout and save the payment screen.

What appears on the credit-card statement?

SnagRx's Terms say OPNLP-SNAGRX.

Is SnagRx's 4.8-star rating independently verified?

Not from the information displayed. The badge on SnagRx's site does not name a review platform or show the number of reviews used.

What should I do if an injectable GLP-1 arrives warm?

Do not use it. FDA advises patients not to use injectable GLP-1 products that arrive warm or without enough refrigeration. Photograph the shipment and contact the dispensing pharmacy and prescribing clinician.

Our final verdict on SnagRx

SnagRx is worth considering only if you're paying cash, a clinician documents why compounded medication fits your case, and you choose the month-to-month plan with your eyes open. It is the wrong choice if you want an FDA-approved brand, insurance help, refund flexibility, clear policy language, or a parent company that has answered its BBB complaints.

The best-looking rates — $69 and $119 — require $828 or $1,428 paid up front. The Terms generally do not refund unused months. The current pages also conflict on denial refunds, charge timing, cancellation, state coverage, and whether refunds exist at all.

Here's what we'd tell a friend: the $99 semaglutide or $149 tirzepatide month-to-month plan is the only SnagRx commitment we would consider. The annual plan is a bet on a parent company that began in December 2025 and has 21 unanswered complaints on its shared BBB file. Thirty dollars a month is a fair price for the right to leave before another full term renews.

Before you pay, confirm six things in writing: the medication, patient-specific reason for compounding, total charge, pharmacy, exact dose and concentration, and cancel-by date.

→ Does that still sound like your situation? Open SnagRx's live intake, choose no plan until you see the full charge, and save every term shown before payment.

Still not sure which GLP-1 path fits? Take the free Find My GLP-1 Path quiz — about 2 minutes.

About this page

Researched and written by The RX Index editorial team. Published August 2026. Last verified: August 11, 2026.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Some links on this page may be affiliate links, which do not affect our findings or verdict. We have not used SnagRx and do not claim firsthand experience with it. This is not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.

Primary sources

• SnagRx homepage
• SnagRx Terms & Conditions — updated July 27, 2026
• SnagRx Cancellation and Refund Policy — updated February 10, 2026
• SnagRx Medical Consent — updated February 10, 2026
• Modern Metabolic Medicine BBB business profile
• Modern Metabolic Medicine BBB complaint file
• Embody Terms & Conditions
• RodeoMeds website
• FDA: Compounding and the FDA — Questions and Answers
• FDA: April 1, 2026 GLP-1 compounding policy update
• FDA: Concerns with unapproved GLP-1 drugs
• FDA: March 3, 2026 telehealth warning-letter announcement
• FDA-approved Zepbound prescribing information on DailyMed
• FDA-approved Wegovy prescribing information on DailyMed
• FDA closeout letter for Triad Rx — May 3, 2023
• Ro current weight-loss pricing
• Ro current insurance information

All sources above were accessed or rechecked August 11, 2026.

Corrections and updates: We update this page when pricing, policies, FDA guidance, state access, or the complaint record changes. If you've used SnagRx and something here does not match your documents or experience, send us the receipt or policy text and we'll check it.